CAPSTAN THERAPEUTICS Trademark

Trademark Overview


On Thursday, March 28, 2024, a trademark application was filed for CAPSTAN THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the CAPSTAN THERAPEUTICS trademark a serial number of 98473585. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, October 10, 2024. This trademark is owned by CAPSTAN THERAPEUTICS, INC.. The CAPSTAN THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; systems to express therapeutic proteins in vivo; biopharmaceuticals; medicines; drugs; vaccines; in vivo cell therapies; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells; gene therapy products; gene therapy preparations; gene therapy products, namely, genetically engineered cells for transplant purposes; targeted in vivo RNA technologies; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms; cell platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gen...
capstan therapeutics

General Information


Serial Number98473585
Word MarkCAPSTAN THERAPEUTICS
Filing DateThursday, March 28, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, October 10, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; systems to express therapeutic proteins in vivo; biopharmaceuticals; medicines; drugs; vaccines; in vivo cell therapies; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells; gene therapy products; gene therapy preparations; gene therapy products, namely, genetically engineered cells for transplant purposes; targeted in vivo RNA technologies; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms; cell platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gene therapy;

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 28, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCAPSTAN THERAPEUTICS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Thursday, March 28, 2024NEW APPLICATION ENTERED
Thursday, March 28, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 10, 2024NON-FINAL ACTION E-MAILED
Thursday, October 10, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 10, 2024NON-FINAL ACTION WRITTEN
Wednesday, October 9, 2024ASSIGNED TO EXAMINER
Tuesday, April 2, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED